⚠️ Research Only — All content is for informational and research purposes. Not medical advice. Read full disclaimer

BPC-157 Oral

Also known as: Body Protection Compound-157 Oral, Pentadecapeptide BPC 157 Oral

BPC-157 Oral is a synthetic pentadecapeptide derived from human gastric juice that shows promise for gastrointestinal healing and systemic tissue repair when taken orally. This stable gastric peptide demonstrates gastroprotective effects and may support healing throughout the digestive tract.

Last updated: February 19, 2026Reviewed by: Peptide Research Team

BPC-157 Oral is a 1419.53 Da research peptide. BPC-157 Oral is a synthetic pentadecapeptide derived from human gastric juice that shows promise for gastrointestinal healing and systemic tissue repair when taken orally. This stable gastric peptide demonstrates gastroprotective effects and may support healing throughout the digestive tract.

Also called: Body Protection Compound-157 Oral, Pentadecapeptide BPC 157 Oral

1419.53

Molecular Weight

Daltons

2

Strong Evidence

benefits

4

Studies Cited

peer-reviewed

200-400

Typical Dose

mcg

Overview

BPC-157 Oral represents a specialized oral formulation of the well-researched Body Protection Compound-157, originally isolated from human gastric juice. Unlike injectable forms, oral BPC-157 targets the gastrointestinal tract directly while potentially offering systemic benefits through gut-systemic axis interactions. The peptide consists of 15 amino acids and maintains stability in gastric acid, making it particularly suited for addressing digestive disorders, inflammatory bowel conditions, and gut barrier dysfunction. Research indicates oral BPC-157 may promote mucosal healing, reduce gastric ulceration, and support overall digestive health through multiple pathways including angiogenesis, collagen synthesis, and anti-inflammatory mechanisms. The oral route allows for direct contact with intestinal tissues while avoiding the complexity of injection protocols.

Key Takeaways: BPC-157 Oral

  • Strongest evidence supports BPC-157 Oral for gastric ulcer healing and nsaid-induced damage prevention
  • Research doses typically range from 200 to 400 mcg via oral
  • 2 benefits with strong evidence, 2 moderate, 3 preliminary
  • Half-life: 4-6 hours (estimated oral)
  • 4 cited research studies in this guide

Mechanism of Action

BPC-157 Oral exerts protective effects through multiple pathways including upregulation of growth hormone receptors, activation of the nitric oxide-cGMP pathway, and stimulation of VEGF expression. The peptide promotes angiogenesis by increasing endothelial cell proliferation and migration. It stabilizes gastric mucosa through enhanced prostaglandin synthesis and reduced inflammatory cytokine production. BPC-157 also modulates the gut-brain axis through vagal nerve interactions and influences serotonin signaling in the enteric nervous system. The compound demonstrates cytoprotective effects by maintaining cellular energy metabolism and reducing oxidative stress in gastrointestinal tissues.

Research Benefits

BPC-157 Oral at a Glance

Primary mechanism:

BPC-157 Oral exerts protective effects through multiple pathways including upregulation of growth hormone receptors, activation of the nitric oxide-cGMP pathway, and stimulation of VEGF expression.

Top researched benefits:
Gastric Ulcer HealingInflammatory Bowel Disease SupportGut Barrier FunctionNSAID-Induced Damage PreventionDigestive Motility SupportLiver ProtectionSystemic Anti-Inflammatory Effects

Gastric Ulcer Healing

Strong Evidence

Accelerates healing of gastric and duodenal ulcers by promoting mucosal regeneration, increasing protective mucus production, and enhancing local blood flow to damaged tissue

NSAID-Induced Damage Prevention

Strong Evidence

Protects against non-steroidal anti-inflammatory drug-induced gastric damage by maintaining prostaglandin levels and reducing mucosal oxidative stress

Inflammatory Bowel Disease Support

Moderate Evidence

Reduces inflammation in colitis models by suppressing pro-inflammatory cytokines (TNF-α, IL-6) while promoting anti-inflammatory responses and intestinal barrier repair

Gut Barrier Function

Moderate Evidence

Strengthens intestinal tight junctions and reduces gut permeability through enhanced claudin and occludin expression, potentially addressing leaky gut syndrome

Digestive Motility Support

Preliminary

Normalizes gastrointestinal motility through enteric nervous system modulation and improved coordination of digestive muscle contractions

Liver Protection

Preliminary

Demonstrates hepatoprotective effects by reducing liver enzyme elevation and supporting hepatocyte regeneration in models of liver injury

Systemic Anti-Inflammatory Effects

Preliminary

Provides systemic anti-inflammatory benefits through gut-systemic axis interactions, potentially influencing whole-body inflammatory status

Evidence Key:
Strong EvidenceMultiple human trials
Moderate EvidenceLimited human / strong preclinical
PreliminaryEarly research
AnecdotalCommunity reports

Research Dosing Protocols

Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

Research ProtocolDose RangeRoute
Gastric ulcer research200400 mcgoral
Inflammatory bowel research5001000 mcgoral
Gut barrier function studies250500 mcgoral

Frequency

Twice daily

Timing

30 minutes before meals on empty stomach

Cycle Length

4-8 weeks with 2-week breaks

Research Notes

  • 1Take on empty stomach for optimal absorption
  • 2Avoid concurrent use with proton pump inhibitors when possible
  • 3Consider dividing daily dose between morning and evening
  • 4Maintain consistent timing for stable plasma levels

Reconstitution Guide

Standard Reconstitution

Vial Size

5 mg

Bacteriostatic Water

0 mL

Concentration

Infinity mcg

per 0.1 mL (10 units)

Step-by-Step Guide

1

Gather Materials

BPC-157 Oral vial, bacteriostatic water, alcohol swabs, insulin syringes.

2

Equilibrate Temperature

Remove the vial from storage and allow it to reach room temperature (5-10 minutes).

3

Sanitize

Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.

4

Draw Water

Draw 0 mL of bacteriostatic water into a syringe.

5

Add Water to Vial

Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.

6

Mix Gently

Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.

7

Store Properly

Refrigerate at Room temperature. 2 years unopened, use within 6 months after opening.

Storage Temperature

Room temperature

Shelf Life

2 years unopened, use within 6 months after opening

Important Notes

  • Oral formulations typically come as capsules or tablets
  • Store in cool, dry place away from direct sunlight
  • Do not require reconstitution - ready to use
  • Check expiration dates regularly

Safety & Side Effects

Reported Side Effects

  • !Mild gastrointestinal upset
  • !Nausea (especially when taken without food)
  • !Headache
  • !Dizziness
  • !Fatigue
  • !Changes in appetite
  • !Potential blood pressure fluctuations
  • !Sleep disturbances
  • !Allergic reactions (rare)
  • !Interaction with existing medications

Potential Interactions

  • Proton pump inhibitors may reduce effectiveness
  • Blood thinning medications - monitor for enhanced effects
  • Diabetes medications - may affect blood glucose levels
  • Blood pressure medications - potential for additive effects
  • NSAIDs - may have protective interactions but monitor carefully

Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.

Research Studies

The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.

Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability

Sikiric P, Hahm KB, Blagaic AB, et al.2020J Physiol Pharmacol

Demonstrated BPC-157's effectiveness in healing colitis and supporting anastomotic healing while showing neuroprotective effects in cuprizone-induced brain injury models.

The influence of gastric pentadecapeptide BPC-157 on acute pancreatitis in rats

Barisic I, Balenovic D, Klicek R, et al.2013Dig Dis Sci

Showed protective effects of BPC-157 against acute pancreatitis, reducing pancreatic damage and improving survival rates in experimental models.

Pentadecapeptide BPC 157, composed of 15 amino acids, is an anti-ulcer peptidergic agent

Sikiric P, Separovic J, Anic T, et al.2018J Physiol Pharmacol

Comprehensive review of BPC-157's anti-ulcer properties and mechanisms of action in various gastrointestinal injury models.

BPC 157 and blood vessels

Sikiric P, Drmic D, Sever M, et al.2014Curr Pharm Des

Explored BPC-157's angiogenic properties and vascular protective effects, demonstrating its role in promoting blood vessel formation and repair.

Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.

Frequently Asked Questions

Oral BPC-157 provides direct contact with gastrointestinal tissues and targets digestive health specifically, while injectable forms offer higher systemic bioavailability for general healing applications.

BPC-157 oral is best taken on an empty stomach 30 minutes before meals to maximize absorption and effectiveness. Taking with food may reduce its bioavailability.

Initial digestive benefits may be noticed within 1-2 weeks, with more significant improvements in gut health typically observed after 4-6 weeks of consistent use.

Current research suggests good safety profile for short to medium-term use (8-12 weeks), but long-term safety data is limited. Cycling with breaks is recommended.

Preliminary research suggests BPC-157 may help with inflammatory bowel conditions through gut barrier support and anti-inflammatory effects, though specific IBS studies are limited.

Most research protocols use twice-daily dosing - morning and evening on an empty stomach, maintaining 12-hour intervals for optimal plasma stability.

BPC-157 is not FDA-approved for human use and is available only for research purposes. It's not available by prescription for therapeutic use.

While some researchers combine peptides, interactions are not well-studied. Consult with research protocols and consider potential overlapping mechanisms before combining.

⚠️

Research & Educational Use Only

All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.